Johnson & Johnson
JNJ
Positions held
Your positionsJNJ isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Johnson & Johnson's strong market position in the healthcare sector allows it to leverage its extensive portfolio of products and innovations to maintain competitive advantages.
- In Q2 2026, JNJ reported a revenue increase of 5% compared to the prior quarter, reaching $25.3 billion.
- The gross margin improved to 68.2% in Q2 2026, up from 66.3% in Q1 2026.
- The healthcare industry faces ongoing regulatory challenges that could impact Johnson & Johnson's operations and profitability.
- Earnings growth for JNJ has been negative at -0.9%, indicating potential struggles in maintaining profitability.
- The company's operating margin decreased from 29.6% in Q3 2025 to 28.3% in Q2 2026, reflecting pressure on operational efficiency.
Fundamentals
| Market cap | $618.09B | Enterprise value | $646.37B | Trailing P/E | 29.72 | Forward P/E | 21.19 |
| PEG | 2.71 | Price / book | 7.27 | Beta | 0.21 | Dividend yield | 2.09% |
| Revenue growth | 6.6% | Earnings growth | -0.9% | Gross margin | 68.1% | Operating margin | 29.2% |
| Profit margin | 21.5% | ROE | 25.7% | ROA | 8.6% | Debt / equity | 0.58 |
| Current ratio | 1.09 | Free cash flow | $16.89B | Analyst recommendation | buy | Mean target | $279.64 |
| 52w high | $281.07 | 52w low | $184.66 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $25.3B | $24.1B | $24.6B | $24.0B | $23.7B | — |
| Op margin | 28.3% | 26.6% | 22.8% | 29.6% | 28.3% | — |
| Net income | $5.5B | $5.2B | $5.1B | $5.2B | $5.5B | — |
| Gross margin | 68.2% | 66.3% | 67.6% | 69.6% | 67.9% | — |
| Gross profit | $17.3B | $16.0B | $16.6B | $16.7B | $16.1B | — |
| Operating income | $7.2B | $6.4B | $5.6B | $7.1B | $6.7B | — |
- Revenue +5% vs prior quarter ($25.3B vs $24.1B).
- Gross margin 68.2% (was 66.3% prior quarter).
- Operating margin expanded to 28.3%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $94.2B | $88.8B | $85.2B | $80.0B | — |
| Op margin | 27.2% | 23.9% | 25.8% | 26.3% | — |
| Net income | $26.8B | $14.1B | $35.2B | $17.9B | — |
| Gross margin | 67.9% | 69.1% | 68.8% | 69.3% | — |
| Gross profit | $63.9B | $61.4B | $58.6B | $55.4B | — |
| Operating income | $25.6B | $21.2B | $22.0B | $21.0B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Earnings Calendar and Analysis for This Week
2026-10-09 · Boston sues J&J subsidiary over alleged patent infringement for cardiology device
2026-10-09 · BofA Securities Adjusts Johnson & Johnson Price Target to $282 From $278, Maintains Neutral Rating
2026-10-09 · Cancer Stocks to Consider as Oncology Innovation Accelerates
2026-10-09 · J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold?
2026-10-09 · 4 Dividend Stocks Boomers Can Safely Buy Now and Hold Forever
2026-10-09 · Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
2026-10-09 · Should You Be Worried About Pfizer Stock?
2026-10-08 · Coca-Cola (NYSE:KO) & Johnson & Johson (NYSE:JNJ): Buy Them For The Dividends, Says Jim Cramer
2026-10-08 · Johnson & Johnson (JNJ) Is Heading Toward A Major Patent Cliff
2026-10-08 · Why High-Yield REITs and BDCs Can Be Powerful Income Stocks Inside a Roth IRA
Price (daily)
Full chart · RSI · MACD · patternsOn Trade and Ticker